Special Issue

Towards Protein Structure and Functional Analysis in Coronavirus and Therapeutic Perspectives

Message from the Guest Editors

Severe acute respiratory syndrome coronavirus (SARS-CoV), Middle-East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are three coronaviruses that cross over the species barrier, leading to severe health problems. Understanding the structure and function of SARS-CoV-2 proteins is important from a therapeutic perspective. Papers focusing on aspects including but not limited to the following are welcome for submission to this Special Issue:

- Computational and experimental studies of coronavirus family virus proteins' structure and function:
- Therapeutic evaluation of coronavirus family virus proteins in perspective drug and vaccine design;
- Evolutionary analysis of coronavirus family virus proteins;
- Mutational analysis of coronavirus family virus proteins;

Machine learning and artificial intelligence in coronavirus family virus protein structure and function analysis.

Guest Editors

Dr. Sajjad Ahmad

Dr. Muhammad Khurram

Dr. Muhammad Tahir-ul-Qamar

Deadline for manuscript submissions

closed (30 November 2023)



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/144794

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

